| Literature DB >> 29018813 |
Yanyan Wu1, Rong Huang1, Xu Zhong1, Yi Xiao1.
Abstract
OBJECTIVES: To explore the cardiovascular effects of nightlong repetitive arousals (RA).Entities:
Mesh:
Substances:
Year: 2017 PMID: 29018813 PMCID: PMC5605864 DOI: 10.1155/2017/4213861
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1The modulation of stimuli based on the consequence of the previous stimulus. Arousal and wakefulness were defined in accordance with the AASM scoring rule. aThe stimuli were presented roughly every 45 seconds in order to achieve the expected arousal index, because not every stimulus would evoke arousal successfully. bThe set of stimulus presented before the current one was considered to be the softer one. cThe strategy to advance stimuli is illustrated in detail in the text.
Figure 2Typical waveform of DVP over a single cardiac cycle. It is derived from a set of real data of the present study. Point A indicates the first peak which is generated by the contraction of left ventricle. Point B is the inflection point which is formed largely by the reflection of pressure from the arteries in the lower extremities back up to the aorta. The time difference between these two points is defined as ΔTDVP.
Characteristics of the subjects.
| Age/y | 25.0 (2.1) |
| Height/m | 1.76 (0.05) |
| Weight/kg | 71 (7) |
| BMI/kg·m−2 | 22.9 (1.9) |
| Sleep duration/h | 7.0 (6.4, 7.0) |
| Baseline AHI/h−1 | 0.30 (0.02, 0.78) |
BMI, body mass index; AHI, apnea-hypopnea index.
Sleep parameters on the control night and the test night.
| Control | Test | |
|---|---|---|
| TST/min | 390 (44) | 368 (54) |
| N1/min | 42 (16, 46) | 39 (17) |
| N2/min | 263 (52) | 248 (40) |
| N3/min | 21 (17) | 4 (0, 16) |
| REM/min | 66 (22) | 70 (22) |
| N1% | 11.2 (4.0, 12.2) | 10.7 (4.3) |
| N2% | 67.1 (8.7) | 68.1 (7.6) |
| N3% | 5.2 (4.2) | 1.3 (0.0, 4.1) |
| REM% | 17.0 (5.6) | 18.4 (4.4) |
| ArI/h−1 | 15.1 (3.1) | 43.9 (9.1)† |
TST, total sleep time; N1, non-rapid-eye movement sleep stage 1; N2, non-rapid-eye movement sleep stage 2; N3, non-rapid-eye movement sleep stage 3; REM, rapid-eye movement sleep; N1%, the percentage of N1; N2%, the percentage of N2; N3%, the percentage of N3; REM%, the percentage of REM; ArI, arousal index; P < 0.05 from control condition; †P < 0.001 from control condition.
Measurements of blood pressure, heart rate variability indices, and stiffness index.
| Control | Test | |||
|---|---|---|---|---|
| Presleep | Postsleep | Presleep | Postsleep | |
| SBP/mmHg | 118 (6) | 116 (6) | 115 (6) | 115 (7) |
| DBP/mmHg△ | 80 (6) | 79 (8) | 80 (5) | 83 (5) |
| LF/n.u.▲ | 54 (16) | 59 (13) | 46 (17) | 72 (12) † |
| HF/n.u.▼ | 46 (16) | 41 (13) | 54 (17) | 28 (12) ‡ |
| LHR▲ | 1.2 (0.8, 1.8) | 1.4 (1.1, 2.1) | 0.7 (0.4, 1.4) | 2.7 (1.8, 5.0) † |
| ASI/m·s−1 | 5.50 (0.44) | 5.55 (0.31) | 5.60 (0.43) | 5.50 (0.45) |
SBP, systolic blood pressure; DBP, diastolic blood pressure; LF, low frequency; HF, high frequency; n.u., normalized units; LHR, low frequency to high frequency ratio; ASI, arterial stiffness index. △The overnight change (postsleep – presleep) under the test condition is higher from that under the control condition with P < 0.05. ▲The overnight change under the test condition is higher from the control condition with P < 0.001. ▼The overnight change under the test condition decreases from the control condition with P < 0.001. Postsleep measurement is increased from the presleep level with P < 0.05. †Postsleep measurement increases from the presleep level with P < 0.001. ‡Postsleep measurement is decreased from the presleep level with P < 0.001.
Measurements of serum markers.
| Control | Test |
| |
|---|---|---|---|
| NO/ | 46 (26) | 46 (18) | N/S |
| ET-1/pg·ml−1 | 1.58 (1.27, 2.68) | 1.59 (1.04, 2.61) | N/S |
| IL-6/pg·ml−1 | 0.63 (0.41, 0.88) | 0.69 (0.46, 1.01) | N/S |
| CRP/pg·ml−1 | 8.8 (4.8, 18.9) | 6.6 (4.6, 18.1) | N/S |
| TNF- | 0.86 (0.82, 0.96) | 0.88 (0.84, 0.94) | N/S |
| VEGF/ng·ml−1 | 0.15 (0.09, 0.23) | 0.14 (0.09, 0.20) | N/S |
NO, nitric oxide; ET-1, endothelin-1; IL-6, interleukin-6; CRP, C-reactive protein; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor; N/S, not significant.
Correlation analysis of HFΔ, LHRΔ, and DBPΔ with sleep parameters.
| DBPΔ | HFΔ | LHRΔ | |
|---|---|---|---|
| TST | −0.006 | −0.439 | 0.424 |
| N1 | 0.125 | −0.131 | −0.169 |
| N2 | −0.034 | −0.133 | 0.188 |
| N3 | 0.251 | −0.120 | 0.112 |
| REM | −0.127 | −0.656 | 0.662 |
| N1% | 0.167 | 0.269 | −0.326 |
| N2% | −0.199 | 0.135 | −0.119 |
| N3% | 0.235 | −0.101 | 0.094 |
| REM% | −0.128 | −0.602 | 0.624 |
| ArI | 0.134 | 0.061 | −0.108 |
ΔT′, relative overnight difference (overnight change/presleep measure) on the test night; DBP, diastolic blood pressure; HF, high frequency power; LHR, low frequency to high frequency ratio; TST, total sleep time; N1, non-rapid-eye movement sleep stage 1; N2, non-rapid-eye movement sleep stage 2; N3, non-rapid-eye movement sleep stage 3; REM, rapid eye movement sleep; N1%, the percentage of N1; N2%, the percentage of N2; N3%, the percentage of N3; REM%, the percentage of REM; ArI, arousal index. The correlation is significant with P < 0.05.
Correlation between DBPΔ and ΔT′ in HRV variables.
| DBPΔ | ||
|---|---|---|
|
|
| |
| HFΔ | 0.096 | N/S |
| LHRΔ | −0.175 | N/S |
ΔT′, relative overnight difference (overnight change/presleep measure) on the test night; DBP, diastolic blood pressure; HF, high frequency power; LHR, low frequency to high frequency ratio; N/S, not significant.